COMPARISON OF COMPLIANCE AND PERSISTENCE WITH IMMUNOMODULATING AGENTS FOR MULTIPLE SCLEROSIS IN A COMMERCIALLY INSURED POPULATION

Author(s)

Terrence Shea, BA, Senior Consultant, Performance Management1, Frank Wood, MBA, Senior Analytic Consultant2, Boyung Shim, MPH, Engagement Manager, Performance Management1, Eitan Becker, BSc, MSc, MBA, Manager, Business Intelligence3, Dennis Meletiche, PharmD, Director, Health Outcomes & Market Access3, Randy Bennett, BA, Medical Director, US Medical Affairs, Neurology3, Ahmad AL-Sabbagh, MD, Vice President, US Medical Affairs, Neurology31IMS Management Consulting, Plymouth Meeting, PA, USA; 2 PharMetrics, Inc., a unit of IMS, Watertown, MA, USA; 3 EMD Serono, Inc, Rockland, MA, USA

Objective: To examine compliance rates, measured with the medication possession ratio (MPR) and 12-month persistence rates of patients initiating 1 of 4 immunomodulating treatments for multiple sclerosis (MS). Methods: The study population consisted of patients aged 18–64 years initiating MS treatment from January 2, 2004, to July 5, 2005. Patients were identified from an administrative claims database (PharMetrics, Inc., Watertown, MA). Patients had continuous health plan enrollment for =12 months before and =15 months after their first MS prescription. The proportion of patients with MPR >85% (appropriate compliance) and 12-month persistence rates (proportion of patients with drug therapy at month 12 without a lapse of therapy >90 d) were evaluated across 4 treatment groups: interferon beta (IFNß)-1a subcutaneous (SC), IFNß-1a intramuscular (IM), IFNß-1b, and glatiramer acetate (GA). Treatment comparisons were evaluated by using Wilcoxon rank sum and chi-square tests for continuous and dichotomous variables, respectively. Results: Immunomodulating treatment was initiated in 3195 patients (IFNß-1a SC, n=799; IFNß-1a IM, n=905; IFNß-1b, n=344, and GA, n=1147). Sex, geographic region, and health plan and product types were similar across all treatment groups. Mean age was statistically higher in the IFNß-1a IM groups vs the IFNß-1a SC and GA groups (44.9 vs 43.5 and 43.8 y, respectively, P<0.01) but not with the IFNß-1b group (44.4 y). Compliance (MPR =85%) was significantly higher with IFNß-1a SC vs IFNß-1b (49.7% vs 39.8%; P=0.002) but not with GA (45.7%) or IFNß-1a IM (48.1%). IFNß-1a SC patients had a persistence rate of 60.3%, significantly higher than that of IFNß-1a IM (54.9%) and IFNß-1b (52.9%; P<0.03, for both) but not GA (60.5%; P=0.936). Conclusion: All 4 groups were comparable in terms of demographic characteristics. Although differences in compliance were less pronounced, the IFNß-1a SC and GA treatment groups had the highest persistence rates.

Conference/Value in Health Info

2008-05, ISPOR 2008, Toronto, Ontario, Canada

Value in Health, Vol. 11, No. 3 (May/June 2008)

Code

PND26

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×